Keywords: results, phase, ii, timi-5, study, ciba, recombinant

RESULTS FROM PHASE II TIMI-5 STUDY

Article | 22 November 1993

Ciba's recombinant hirudin increases artery patency after myocardial infarction over and above that seen with heparin, according to the results ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genentech

Go to company listing

Related Drugs

Heparin

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Activase

Go to drug listing